KRAS and metastatic malignant neoplasm in the lymph nodes: In addition, the status of lymph node metastasis was also an independent risk factor for the prognosis of patients with KRAS mutations (HR 2.274, 95% CI, 1.028–5.031 log‐rank test, p < 0.05).